Telehealth Expansion Raises Concerns Over GLP-1 Drug Safety and Oversight
The surge in telehealth services has led to increased accessibility to GLP-1 medications, commonly used for weight loss, but has also raised significant safety concerns. Karleigh McClain, a compliance consultant from Tennessee, experienced severe side effects after receiving a high dosage of a GLP-1 drug prescribed via telehealth. This incident highlights the broader issue of medication errors associated with telehealth prescriptions. The expansion of telehealth, initially intended to improve healthcare access during the COVID-19 pandemic, has resulted in varied practices across states, with some companies offering quick prescriptions without adequate patient evaluation. Critics argue that this ease of access may lead to inappropriate prescriptions and insufficient follow-up care, potentially compromising patient safety. 
